Pressed by a Supreme Court decision that could cost universities billions of dollars in royalties, institutions are fine-tuning their intellectual property agreements with researchers.
The short-term impact of these new forms, which assign IP rights to research institutions, is a few lost minutes to sign on the dotted line. The long-term affect, one expert argues, could cripple innovation in a range of fields, including drug development.
No comments:
Post a Comment